Myeloproliferative neoplasm

Jump to navigation Jump to search

Template:DiseaseDisorder infobox

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm

on Myeloproliferative neoplasm

Myeloproliferative neoplasm in the news

Blogs on Myeloproliferative neoplasm

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Myeloproliferation, myeloproliferative disorder, myeloproliferative neoplasm

Overview

The MPNs are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid lineages in the bone marrow with relatively normal maturation resulting in increased numbers of granulocytes, red blood cells and platelets in the peripheral blood. This is in contrast to the ineffective erythropoiesis usually observed in the myelodysplastic syndromes.Sequestration of excess blood cells in the spleen or liver, extramedullary hematopoiesis and leukemic cells infiltration, these events either alone or in combination were found to cause spleenomegaly and hepatomegaly.

MPNs can undergo clonal evolution and step wise progression to bone marrow failure or transformation to an acute blast phase. Cytogenetic or molecular evidence of clonal evolution usually indicates the onset of an acceleration stage or of transformation to an acute process. An increase in the percentage of blasts in the blood or bone marrow is also an indication of worsening disease. The finding of less than 20 % of blasts in the blood or bone marrow signifies acceleration and more than 20% of blasts is sufficient to diagnose a blast phase.


Leukocytosis , Thrombocytosis, excessive magaryocytic proliferation , myelofibrosis and organomegaly are the features that can overlap among the myeloproliferative diseases and complicate the the diagnosis of specific disease entities. For CML, the BCR/ABL fusion gene, in association with characteristic morphologic and clinical findings permits an unequivocal diagnosis.

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myeloproliferative disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:Hematology


ar:مرض التكاثر النقوي de:Myeloproliferative Erkrankung


Template:WikiDoc Sources